Director of Cell and Gene Therapy Facility, Institute for Stem Cell Biology and Medicine
Member of the Healthcare Council
Antoni Ribas, MD, is Associate Professor of Medicine and Surgery at University of California, Los Angeles. He focuses on new drug development for melanoma, and has an NIH-funded research laboratory focused also in melanoma. He serves as Director of the Cell and Gene Therapy Core Facility, Assistant Director of the Tumor Immunology Program, Assistant Director of the Human Gene Medicine Program, General Clinical Research Center Advisory Board Member, and trains faculty at the Institute for Stem Cell Biology and Medicine. He has published over 100 manuscripts and book chapters in the field of melanoma. Dr. Ribas is a permanent committee member of the NCI grant review panels. Dr. Ribas' clinical and laboratory research involves the development of novel strategies for the treatment of cancer, including anti-CTLA4 antibodies, cancer vaccines, BRAF inhibitor and Mek inhibitor targeted therapy, nanoparticle delivery of siRNA, and gene therapy strategies. (This is me - Update Profile)
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
Antoni Ribas has not published any GLG News Analyses.
| Study Group Name | No. Members |
|---|---|
| Oncologists (US) | 2218 |
| Physicians who Treat Malignant Melanoma (US) | 220 |
| Skin Cancer Oncologists (US) | 102 |
| GI Cancer Oncologists (US) | 87 |
| Nexavar Prescribers: Oncologists | 78 |
Antoni Ribas has not participated in any GLG Live Meetings.